{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:42Z","timestamp":1785168282003,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.jhep.2013.11.024","type":"journal-article","created":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T11:32:11Z","timestamp":1385897531000},"page":"715-722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients"],"prefix":"10.1016","volume":"60","author":[{"given":"Thomas","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sing","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Kitrinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John F.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.11.024_b0005","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMe0808185","article-title":"Chronic hepatitis B \u2013 new goals, new treatment","volume":"359","author":"Lai","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.024_b0010","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate vs. adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.024_b0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.024_b0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2013.11.024_b0025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.024_b0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jhep.2007.12.006","article-title":"Potency of tenofovir in chronic hepatitis B: mono or combination therapy?","volume":"48","author":"Reijnders","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.024_b0035","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.024_b0040","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/j.1365-2893.2011.01479.x","article-title":"Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance","volume":"18","author":"Park","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2013.11.024_b0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.024_b0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.024_b0055","unstructured":"Marcellin P, Heathcote EJ, Corsa A, Liu Y. No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240weeks of treatment in patients with HBeAg+ and HBeAg\u2212 chronic hepatitis B virus infection. In: 62nd annual meeting of the American Association for the Study of Liver Diseases, November 4\u20138, San Francisco, CA; 2011."},{"key":"10.1016\/j.jhep.2013.11.024_b0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.24078","article-title":"No resistance to tenofovir disoproxil fumarate detected after up to 144weeks of therapy in patients monoinfected with chronic hepatitis B virus","volume":"53","author":"Snow-Lampart","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.024_b0065","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.024_b0070","first-page":"699A","article-title":"Presence of rtA194T at baseline does not reduce efficacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B","volume":"48","author":"Fung","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.024_b0075","doi-asserted-by":"crossref","unstructured":"Levrero M, Cimino L, Lampertico P. Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV\/LAM treatment: results of the OptiB Italian Multicenter Prospective Open Label Study. In: Annual meeting of the American Association for the Study of Liver Diseases, October 29\u2013November 2, Boston, MA; 2010.","DOI":"10.1016\/S0168-8278(10)61011-2"},{"key":"10.1016\/j.jhep.2013.11.024_b0080","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1365-2036.2011.04833.x","article-title":"Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir","volume":"34","author":"Ong","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.11.024_b0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/gut.2010.223206","article-title":"Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B","volume":"60","author":"Patterson","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2013.11.024_b0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van B\u00f6mmel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.024_b0095","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2010.06.053","article-title":"Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection","volume":"139","author":"Berg","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.024_b0100","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jviromet.2011.03.006","article-title":"HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A\u2013H and its use in antiviral phenotyping assays","volume":"173","author":"Zhu","year":"2011","journal-title":"J Virol Methods"},{"key":"10.1016\/j.jhep.2013.11.024_b0105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cgh.2012.04.008","article-title":"Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B","volume":"10","author":"Gish","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.11.024_b0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.2010.236133","article-title":"Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2013.11.024_b0115","doi-asserted-by":"crossref","unstructured":"Lavocat F, Pichoud C, Deny P, Borroto-Esoda K, Sorbel J, Rousseau F, et al. Evolution of viral load and genome sequence in a clinical trial of tenofovir\/emtricitabine combination vs. tenofovir monotherapy for patients with previous adefovir dipivoxil failure. In: Annual meeting of the European Association for the Study of the Liver, April 22\u201326; Copenhagen, Denmark; 2009.","DOI":"10.1016\/S0168-8278(09)60936-3"},{"key":"10.1016\/j.jhep.2013.11.024_b0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2893.2012.01638.x","article-title":"Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen","volume":"20","author":"Svarovskaia","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2013.11.024_b0125","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2013.11.024_b0130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2011.07.003","article-title":"Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study","volume":"92","author":"Si-Ahmed","year":"2011","journal-title":"Antiviral Res"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781300826X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781300826X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:32:26Z","timestamp":1759174346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882781300826X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S016882781300826X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.11.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2013.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}